日本語フィールド
著者：*Wayne H-H Sheu, Yutaka Seino, Elise Chia-Hui Tan, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Wook-Jin Chung, Koichi Node, Atsutaka Yasui, Wei-Yu Lei, Sunwoo Lee, Anastasia Ustyugova, Riho Klement, Anouk Deruaz-Luyet, Moe H Kyaw, Dae Jung Kim, EMPRISE East Asia study group題名：Healthcare resource utilization in patients treated with empagliflozin in East Asia 発表情報：J Diabetes Investig 巻: 13 号: 5 ページ: 810-821キーワード：Asia; Health Resources; Sodium-Glucose Transporter 2 Inhibitors概要：Aims/introduction: We investigated healthcare resources utilization in type 2 diabetes (T2D) patients treated with empagliflozin, a sodium-glucose co-transporter-2 inhibitor, versus dipeptidyl peptidase-4 (DPP-4) inhibitors in clinical practice in Japan, South Korea and Taiwan.
Materials and methods: We analyzed the Japanese Medical Data Vision database (December 2014-April 2018), the South Korean National Health Information Database and the Taiwanese National Health Insurance claims database (both May 2016-December 2017). T2D patients initiating empagliflozin, 10 or 25 mg, or a DPP-4 inhibitor were matched 1:1 via propensity scores (PS). We compared inpatient care needs, emergency room (ER) visits, and outpatient visits between treatment groups using Poisson regression and Cox proportional hazards models, pooled across countries by random-effects meta-analysis.
Results: We identified 28,712 pairs of PS-matched patients; mean follow-up was 5.7-6.8 months. Empagliflozin-treated patients had 27% lower risk of all-cause hospitalization compared with DPP-4 inhibitor-treated patients (rate ratio [RR] 0.73, 95% CI 0.67-0.79), and 23% reduced risk for first hospitalization (hazard ratio 0.77, 95% CI 0.73-0.81). Risk for ER visit was 12% lower with empagliflozin than DPP-4 inhibitors (RR 0.88, 95% CI 0.83-0.94) while risk for outpatient visit was 4% lower (RR 0.96, 95% CI 0.96-0.97). These findings were generally consistent across countries, regardless of baseline cardiovascular disease, and in the subgroup initiating empagliflozin with the 10 mg dose.
Conclusions: Empagliflozin treatment was associated with lower inpatient care needs and other healthcare resource utilization than DPP-4 inhibitors in routine clinical practice in East Asia in this study.抄録：英語フィールド
Author：*Wayne H-H Sheu, Yutaka Seino, Elise Chia-Hui Tan, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Wook-Jin Chung, Koichi Node, Atsutaka Yasui, Wei-Yu Lei, Sunwoo Lee, Anastasia Ustyugova, Riho Klement, Anouk Deruaz-Luyet, Moe H Kyaw, Dae Jung Kim, EMPRISE East Asia study groupTitle：Healthcare resource utilization in patients treated with empagliflozin in East Asia Announcement information:J Diabetes Investig Vol: 13 Issue: 5 Page: 810-821Keyword：Asia; Health Resources; Sodium-Glucose Transporter 2 InhibitorsAn abstract：Aims/introduction: We investigated healthcare resources utilization in type 2 diabetes (T2D) patients treated with empagliflozin, a sodium-glucose co-transporter-2 inhibitor, versus dipeptidyl peptidase-4 (DPP-4) inhibitors in clinical practice in Japan, South Korea and Taiwan.
Materials and methods: We analyzed the Japanese Medical Data Vision database (December 2014-April 2018), the South Korean National Health Information Database and the Taiwanese National Health Insurance claims database (both May 2016-December 2017). T2D patients initiating empagliflozin, 10 or 25 mg, or a DPP-4 inhibitor were matched 1:1 via propensity scores (PS). We compared inpatient care needs, emergency room (ER) visits, and outpatient visits between treatment groups using Poisson regression and Cox proportional hazards models, pooled across countries by random-effects meta-analysis.
Results: We identified 28,712 pairs of PS-matched patients; mean follow-up was 5.7-6.8 months. Empagliflozin-treated patients had 27% lower risk of all-cause hospitalization compared with DPP-4 inhibitor-treated patients (rate ratio [RR] 0.73, 95% CI 0.67-0.79), and 23% reduced risk for first hospitalization (hazard ratio 0.77, 95% CI 0.73-0.81). Risk for ER visit was 12% lower with empagliflozin than DPP-4 inhibitors (RR 0.88, 95% CI 0.83-0.94) while risk for outpatient visit was 4% lower (RR 0.96, 95% CI 0.96-0.97). These findings were generally consistent across countries, regardless of baseline cardiovascular disease, and in the subgroup initiating empagliflozin with the 10 mg dose.
Conclusions: Empagliflozin treatment was associated with lower inpatient care needs and other healthcare resource utilization than DPP-4 inhibitors in routine clinical practice in East Asia in this study.